Phase I open-label study of the respiratory syncytial virus monoclonal antibody clesrovimab: Safety and tolerability in healthy Chinese participants

Phase I open-label study of the respiratory syncytial virus monoclonal antibody clesrovimab: Safety and tolerability in healthy Chinese participants

In China, respiratory syncytial virus (RSV) is the primary cause of acute lower respiratory tract infections (LRTIs), particularly in infants and young children. Clesrovimab is a half-life‒extended RSV neutralizing monoclonal antibody for the prevention of RSV-associated LRTIs in infants. This Phase...

Full description

Saved in:
Bibliographic Details
Main Authors: Yulei He, Fengli Zhao, Xiao Yang, Shasha Xing, Feifeng Xi, Fen Shen, Lin Yang, Guijun Ning, Fang Sun, Rui Wang, Qiong Shou, Rong Fu, Chang Chen, Anushua Sinha, Xueyan Liao
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Healthy subjects
infectious disease
monoclonal antibodies
Phase I
respiratory
safety
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2025.2516948
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/21645515.2025.2516948

Similar Items